Published online 19 February 2009
Haematologica, Vol 94, Issue 4, 576-580 doi:10.3324/haematol.2008.002352
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Elliott, J.
Right arrow Articles by Johnston, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elliott, J.
Right arrow Articles by Johnston, J. A.

Myeloproliferative Disorders

SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases

Joanne Elliott1, Yvonne Suessmuth1, Linda M. Scott2, Krystyna Nahlik1, Mary Frances McMullin3, Stefan N. Constantinescu4, Anthony R. Green2, James A. Johnston1

1 Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Ireland
2 Dept. of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
3 Belfast City Hospitals Trust and Centre for Cancer Research and Cell Biology (CCRCB), Belfast, N. Ireland
4 Ludwig Institute for Cancer Research and The Christian de Duve Institute for Cellular Pathology, Université Catholique de Louvain, Brussels, Belgium

Correspondence: James A. Johnston, Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, QUB, 2nd floor, Whitla Medical Building, 97 Lisburn Rd, Belfast, BT9 7BL, Northern Ireland. E-mail:jim.johnston{at}qub.ac.uk

JAK2 V617F, identified in the majority of patients with myeloproliferative neoplasms, tyrosine phosphorylates SOCS3 and escapes its inhibition. Here, we demonstrate that the JAK2 exon 12 mutants described in a subset of V617F-negative MPN cases, also stabilize tyrosine phosphorylated SOCS3. SOCS3 tyrosine phosphorylation was also observed in peripheral blood mononuclear cells and granulocytes isolated from patients with JAK2 H538QK539L or JAK2 F537-K539delinsL mutations. JAK kinase inhibitors, which effectively inhibited the proliferation of cells expressing V617F or K539L, also caused a dose-dependent reduction in both mutant JAK2 and SOCS3 tyrosine phosphorylation. We propose, therefore, that SOCS3 tyrosine phosphorylation may be a novel bio-marker of myeloproliferative neoplasms resulting from a JAK2 mutation and a potential reporter of effective JAK2 inhibitor therapy currently in clinical development.

Key words: myeloproliferative neoplasms, JAK2, V617F, exon 12, SOCS3.